Skip to content

Wave Life Sciences WVE Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$241K-98.5%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$57.3M+2,457%
ALN
Alnylam PharmaceuticalsALNY
$13.16M-73.3%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.03M+182%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$0-100%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
Enterprise value$615.92M-22.3%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Debt / equity-0.1×
Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's stock issuance proceeds?
Wave Life Sciences (WVE) reported stock issuance proceeds of $1.93M in Q1 2026.
How has Wave Life Sciences's stock issuance proceeds changed year-over-year?
Wave Life Sciences's stock issuance proceeds decreased by 21.1% year-over-year, from $2.45M to $1.93M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.